Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.53 |
| ▸ | DRD4 | P21917 | 4/20 | 0.51 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 3/20 | 0.49 |
| ▸ | DRD3 | P35462 | 3/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7621718 | 1.00 | HRH3 (0.53) | HRH3DRD4ALDH3A1DRD2DRD3 | |
| SCHEMBL10384122 | 1.00 | HRH3 (0.53) | HRH3DRD4ALDH3A1DRD2DRD3 | |
| SCHEMBL7390013 | 1.00 | HRH3 (0.53) | HRH3DRD4ALDH3A1DRD2DRD3 | |
| SCHEMBL1172364 | 0.98 | DRD4 (0.53) | HRH3DRD4ALDH3A1DRD2DRD3 | |
| SCHEMBL4747583 | 0.94 | LTA4H (0.50) | HRH3DRD4ALDH3A1DRD2DRD3 | |
| SCHEMBL17233002 | 0.94 | HRH3 (0.49) | HRH3DRD4ALDH3A1DRD2DRD3 | |
| SCHEMBL4754349 | 0.91 | DRD4 (0.55) | HRH3DRD4ALDH3A1DRD2DRD3 | |
| SCHEMBL28820095 | 0.89 | DRD4 (0.47) | HRH3DRD4ALDH3A1DRD2DRD3 | |
| SCHEMBL11567216 | 0.89 | ALDH3A1 (0.47) | HRH3DRD4ALDH3A1DRD2DRD3 | |
| SCHEMBL4743108 | 0.89 | ALDH3A1 (0.47) | HRH3DRD4ALDH3A1DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6706739-B2 | TREATING ENTEROVIRUS INFECTION | NATIONAL HEALTH RESEARCH INSTITUTE (TW) | 2004-03-16 | — | — | US | disclosed |
| US-20030087936-A1 | Imidazolidinone compounds | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2003-05-08 | — | — | US | disclosed |
| US-6417192-B1 | DRUGS WITH PYRIMIDONE COMPOUNDS INHIBITORS OF THE ENZYME LDL PLA.SUB.2 AND THEREFORE OF USE IN TREATING ATHEROSCLEROSIS. | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-07-09 | — | — | US | disclosed |
| US-4171376-A | Aryloxyalkyl keto-esters | STERLING DRUG INC. (US) | 1979-10-16 | — | — | US | disclosed |
| US-4154850-A | Certain di-(substituted phenoxy) alkanes and hypolipidaemic use thereof | BEECHAM GROUP LIMITED (GB) | 1979-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087936-A1 | Imidazolidinone compounds | EIF2AK2, ZC3HAV1, EMG1 | HRH3 365/4885DRD4 2759/4885ALDH3A1 4712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.